posted
The Immune Response Corporation Secures Key Partners for Launch of Phase II Trial of NeuroVax(TM) In Patients with Multiple Sclerosis
October 10, 2006 09:00:00 (ET)
CARLSBAD, Calif., Oct 10, 2006 /PRNewswire-FirstCall via COMTEX/ -- The Immune Response Corporation (IMNR, Trade) today announced that it has entered into an agreement with Accelsiors CRO & Consultancy Services, a clinical research organization (CRO) with extensive experience in conducting multiple sclerosis (MS) trials, to oversee the 200-patient Phase II trial of NeuroVax(TM), an investigational T-cell receptor (TCR) peptide vaccine for the treatment of MS.
-------------------- LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT!
IP: Logged |